Clinical Trials

Clinical Trial Number: SP002

BioHealx® Anal Fistula Device Post Market Surveillance Study

Study ID: SP002
Phase N/A
Physician Investigator(s)
Study Locations

This post market surveillance study is a single arm multicenter study to demonstrate the long-term durability and effectiveness of the BioHealx Anal Fistula Device for fistula-in-ano closure (internal and external fistula openings).

Eligibility Criteria

Inclusion Criteria:

  • Age 18 - 75 years
  • Presence of Single Continuous Anal Fistula presenting for initial curative surgery
  • Failed or Recurrent Anal Fistula Closure
  • Minimum of 6-weeks of draining seton placed prior to procedure.
  • Availability for follow-up contacts and willingness to complete the Informed Consent.

Exclusion Criteria:

  • Fistula tract shorter than 2cm
  • omplex fistula tract (branching)
  • Body Mass Index > 35
  • Known uncontrolled diabetes or other systemic condition associated with impaired healing
  • Known HIV-positive or immunocompromised
  • Rectal prolapse
  • Pregnancy
  • Rectal / fistula malignancy
  • Crohn's disease
  • Ulcerative proctitis
  • Hidradenitis suppurativa of the anal region
  • Pilonidal sinus disease
  • Presence of hemorrhoid Involving fistula site
  • Continuous use of anti-inflammatory
  • Intersphincteric fistula in ano or fistula treatable by simple fistulotomy
  • Active infection or abscess involving fistula site
  • Known allergy to PLGA material
  • Any severe acute or uncontrolled chronic disease that according to the investigator might render the patient unsuitable for the study
  • Treatment with an investigational drug or medical device in the past 30 days